Rhumbline Advisers Seres Therapeutics, Inc. Transaction History

Rhumbline Advisers

$103 Billion
Q1 2024

A detailed history of Rhumbline Advisers transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 141,453 shares of MCRB stock, worth $101,846. This represents 0.0% of its overall portfolio holdings.

Number of Shares

141,453

Previous 137,519 2.86%

Holding current value

$101,846

Previous $192,000 43.75%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$0.75 - $1.56 $2,950 - $6,137	3,934 Added 2.86%	141,453 $108,000
Q4 2023 Feb 08, 2024	BUY	$0.93 - $2.15 $885 - $2,046	952 Added 0.7%	137,519 $192,000
Q3 2023 Nov 09, 2023	BUY	$2.33 - $5.07 $4,117 - $8,958	1,767 Added 1.31%	136,567 $325,000
Q2 2023 Aug 08, 2023	BUY	$4.67 - $6.55 $189,125 - $265,261	40,498 Added 42.95%	134,800 $645,000
Q1 2023 May 11, 2023	BUY	$4.95 - $6.09 $23,210 - $28,556	4,689 Added 5.23%	94,302 $535,000

Q4 2022 Feb 14, 2023	BUY	$5.09 - $9.05 $8,597 - $15,285	1,689 Added 1.92%	89,613 $502,000
Q3 2022 Nov 10, 2022	BUY	$3.5 - $7.2 $33,106 - $68,104	9,459 Added 12.06%	87,924 $564,000
Q2 2022 Aug 11, 2022	SELL	$2.7 - $7.62 $11,105 - $31,341	-4,113 Reduced 4.98%	78,465 $269,000
Q1 2022 May 12, 2022	SELL	$6.3 - $8.84 $1,058 - $1,485	-168 Reduced 0.2%	82,578 $588,000
Q4 2021 Feb 10, 2022	BUY	$6.02 - $11.43 $7,097 - $13,475	1,179 Added 1.45%	82,746 $689,000
Q3 2021 Nov 12, 2021	BUY	$5.46 - $22.6 $14,851 - $61,472	2,720 Added 3.45%	81,567 $568,000
Q2 2021 Aug 05, 2021	BUY	$18.46 - $24.36 $152,184 - $200,823	8,244 Added 11.68%	78,847 $1.88 Million
Q1 2021 May 06, 2021	SELL	$17.66 - $28.92 $88,706 - $145,265	-5,023 Reduced 6.64%	70,603 $1.45 Million
Q4 2020 Feb 10, 2021	BUY	$23.25 - $37.73 $219,526 - $356,246	9,442 Added 14.27%	75,626 $1.85 Million
Q3 2020 Nov 12, 2020	BUY	$3.74 - $28.74 $37,706 - $289,756	10,082 Added 17.97%	66,184 $1.87 Million
Q2 2020 Aug 13, 2020	BUY	$3.04 - $6.2 $30,919 - $63,060	10,171 Added 22.14%	56,102 $267,000
Q4 2019 Feb 05, 2020	BUY	$2.99 - $4.42 $10,713 - $15,836	3,583 Added 8.46%	45,931 $158,000
Q3 2019 Oct 23, 2019	BUY	$2.29 - $4.16 $12,595 - $22,880	5,500 Added 14.93%	42,348 $170,000
Q2 2019 Aug 14, 2019	BUY	$2.28 - $7.35 $22,699 - $73,176	9,956 Added 37.02%	36,848 $119,000
Q1 2019 May 01, 2019	SELL	$4.83 - $7.21 $1,178 - $1,759	-244 Reduced 0.9%	26,892 $185,000
Q4 2018 Jan 31, 2019	BUY	$4.52 - $8.88 $40,205 - $78,987	8,895 Added 48.76%	27,136 $123,000
Q3 2018 Nov 07, 2018	SELL	$7.33 - $9.23 $9,712 - $12,229	-1,325 Reduced 6.77%	18,241 $138,000
Q2 2018 Aug 06, 2018	BUY	$6.91 - $9.55 $5,838 - $8,069	845 Added 4.51%	19,566 $168,000
Q1 2018 May 02, 2018	SELL	$7.34 - $11.16 $2,679 - $4,073	-365 Reduced 1.91%	18,721 $137,000
Q4 2017 Feb 09, 2018	SELL	$9.15 - $12.64 $33,681 - $46,527	-3,681 Reduced 16.17%	19,086 $194,000
Q3 2017 Nov 06, 2017	BUY	$12.81 - $16.85 $291,645 - $383,623	22,767	22,767 $365,000

Others Institutions Holding MCRB

# of Institutions

100

Shares Held

62.7M

Call Options Held

36.9K

Put Options Held

476K

View Full List

About Seres Therapeutics, Inc.

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $89.3M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

More about MCRB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Seres Therapeutics, Inc. Transaction History